Clinical trials: Congestive Heart Failure Chronic
Chronic Heart Failure
A Clinical Trial to Compare the Pharmacokinetics and Safety of "BR1016C" With "BR1016D" in Healthy Volunteers
To evaluate the pharmacokinetic properties and safety of "BR1016C" and "BR1016D" in healthy adults.
- Trial name
- NCT05102266
- Testing
- BR1016C, BR1016D
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Chronic Heart Failure, Iron-deficiency
Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency
This study aims to evaluate the effect of standard heart failure therapy plus oral solution with protein succinylate iron compared to placebo on the primary end point of 6 minute walk distance at 24th week in patients with…
- Trial name
- NCT03344523
- Testing
- Iron protein succinylate oral solution, standard treatment
- Volunteers
- 600 people
- Sponsor
- Lee's Pharmaceutical Limited
Heart Failure, Heart Failure With Reduced Ejection Fraction
Effectiveness of CRD-740 in Heart Failure
This is a study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
- Trial name
- CARDINAL-HF (NCT05409183)
- Testing
- CRD-740
- Where
- 34 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Chronic Heart Failure With Preserved Ejection Fraction
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical limitation score) compared to placebo after…
- Trial name
- VITALITY-HFpEF (NCT03547583)
- Testing
- Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets
- Where
- 177 sites in United States, Argentina and 19 more
- Volunteers
- 789 people
- Sponsor
- Bayer
Cardiovascular Disease
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration
- Trial name
- NCT04686591
- Testing
- AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
COPD, Chronic Obstructive Pulmonary Disease
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Sensorum Health (Sensorum) is conducting a pilot study to determine if Sensorum's proprietary passive sensor network can be used to identify signals of early health decompensation in subjects prior to a hospitalization for…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, COPD Exacerbation, CHF
- Trial name
- NCT05865184
- Testing
- Data collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sensorum Health Inc.
Chronic Heart Failure, Iron Deficiency
EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure
This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory…
- Conditions
- Chronic Heart Failure, Iron Deficiency, Iron Deficiency Anemia, Anaemia
- Trial name
- EFFICACY-HF (NCT00821717)
- Testing
- Ferinject ® (Ferric carboxymaltose), Normal saline (0.9%)
- Where
- 41 sites in Denmark, France and 3 more
- Volunteers
- 35 people
- Sponsor
- Vifor Pharma
Heart Failure
Investigating the Role of Impella 2.5 System in Acutely Decompensated Chronic Heart Failure Patients
The primary objective of this study is to assess safety and feasibility of IMPELLA 2.5 in Acute Decompensated Heart Failure patients.
- Trial name
- RELIEF I (NCT01185691)
- Testing
- Impella 2.5
- Volunteers
- 1 people
- Sponsor
- Abiomed Inc.
Chronic Heart Failure
Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure
This study evaluated changes in healthcare resource utilization (HCRU) and costs of care within 12 months following initiation of sacubitril/valsartan (sac/val) in commercially insured and Medicare Advantage (MA) lives in the U.S…
- Trial name
- NCT05613140
- Testing
- sacubitril/valsartan
- Where
- United States
- Volunteers
- 9,230 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States
This is an observational study in which data already collected from people with chronic heart failure with reduced ejection fraction (HFrEF) are studied.
- Trial name
- HOVER (NCT06363110)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bayer
Heart Failure With Reduced Ejection Fraction, HFrEF
VisONE Heart Failure Study: Pilot
The VisONE HF pilot is a feasibility pilot for evaluating the benefits and risks of chronically delivering Asymptomatic Diaphragmatic Stimulation in medical refractory heart failure patients using the VisONE™ implantable system…
- Trial name
- NCT03484780
- Testing
- VisONE ADS
- Where
- 3 sites in Georgia, Ukraine
- Volunteers
- 15 people
- Sponsor
- VisCardia Inc.
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer
Heart Failure
Chronic Heart Failure Therapy Optimization With CardioRenal Remote Monitoring System (HERMESHF)
This clinical study evaluates short-term feasibility and safety of CardioRenal ExpHeart in patients with worsening heart failure with reduced ejection fraction to optimize pharmacological heart failure treatment.
- Trial name
- HERMESHF (NCT04050904)
- Testing
- ExpHeart
- Volunteers
- 30 people
- Sponsor
- CardioRenal
Heart Failure
Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure
A Phase 1-2a Study of CXL-1020-01 in Patients with Stable Heart Failure
- Trial name
- NCT01092325
- Testing
- CXL-1020, CXL-1020 Dose for Echo Cohort A, CXL-1020 Doses for Echo Cohort B
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Bristol-Myers Squibb
Lower Extremity Edema, Lower Extremity Edema Chronic
Pedal Pump Clinical Trial on Edema V2
Previous research on the osteopathic manual technique entitled "Pedal Pump" has shown health benefits, specifically increasing lymphatic flow, decreasing lower extremity edema, and decreasing serum lactic acid after maximal…
- Conditions
- Lower Extremity Edema, Lower Extremity Edema Chronic, CHF - Congestive Heart Failure, CHF Exacerbation
- Trial name
- NCT07809516
- Testing
- Pedal Pump
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Hillcrest
Chronic Heart Failure
South Korean Pitavastatin Heart Failure Study
We want to evaluate the utility of statins on heart function according to potency. Patients with chronic ischemic heart failure are administered pitavastatin 4mg or pravastatin 10mg for 52 weeks.
- Trial name
- SAPHIRE (NCT00701285)
- Testing
- pitavastatin, pravastatin
- Where
- South Korea
- Volunteers
- 70 people
- Sponsor
- JW Pharmaceutical
Atrial Fibrillation
Efficacy and Safety Study of F373280
The purpose of this study is to assess the efficacy of F373280 on the maintenance of normal cardiac rhythm after direct electric cardioversion in patients with persistent atrial fibrillation and cardiac failure.
- Trial name
- NCT01831856
- Testing
- 1g of F373280
- Where
- 20 sites in Czechia, Hungary and 3 more
- Volunteers
- 135 people
- Sponsor
- Pierre Fabre Medicament
Congestive Heart Failure Chronic, Low Ejection Fraction
Evaluation of the HeartLogic Diagnostic in Optimizing Guideline-directed Medical Therapy in Patients With Congestive Heart Failure and Chronically Low Ejection Fractions (EFs)
The goal of this trial is to determine if the addition of the Heart Logic diagnostic alerts to standard of care therapies will lessen hospitalizations and improve quality of life in patients with heart failure.
- Trial name
- Heartlogic ISR (NCT07412626)
- Testing
- Heartlogic Diagnostic Tool Threshold Change, Heartlogic Diagnostic Tool Unchanged Threshold
- Where
- 2 sites in United States
- Volunteers
- 135 people
- Sponsor
- Robert Pickett
Heart Failure
Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study
Lead survivability will be summarized.
- Trial name
- NCT02294331
- Where
- 100 sites in United States, Belgium and 6 more
- Volunteers
- 1,900 people
- Sponsor
- Medtronic
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim